Given that one of the mechanisms of sorafenib resistance is the overexpression of MET in HCC cells (Wu et al., 2024; Xiang et al., 2014), the additional inhibitory effects of cabozantinib on MET make it a preferred second-line treatment option for patients who have developed resistance to sorafenib. Here, MET is linked to hepatocellular carcinoma.